Medicare for All is back as a campaign plank for Democrats running in Michigan and Texas, with Bernie Sanders again pushing the idea of single-payer universal health coverage.
The debate is not new. In 2019, progressive Senate Democrats tried to advance a Medicare for All bill that would have ended private health insurance and given the government total control over health care, with an estimated price tag of $33 trillion over 10 years.
Supporters say the system would expand coverage. Critics say it would put Washington in charge of care. The source argues the model is unaffordable, hard to administer, and likely to force rationing. It points to Canada and the U.K., where patients face long waits and state systems use centralized rules to decide who gets treatment.
The same concern shows up in drug approval. Monoclonal antibodies, which can be engineered to target cancer, autoimmune disorders, and infectious diseases, are described as being held up while other treatments, such as vaccines, move faster through the FDA.
Why it matters: this is a fight over who gets the final say in medicine — patients and doctors, or federal bureaucrats.
The bottom line: Medicare for All is being sold as access, but its critics see more bureaucracy, more control, and less freedom in the health-care market.